We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Revlimid Delay Caused by 'Workflow' Issue, Celgene Says
Revlimid Delay Caused by 'Workflow' Issue, Celgene Says
October 7, 2005
The FDA has delayed its decision on Celgene's oral blood cancer drug Revlimid, pending further review of the firm's risk management plan for the drug, but Celgene hastened to say that the delay is only due to a paperwork backup.